Africa: New vaccine 'to cut malaria risk by half'

A new vaccine against malaria will help reduce African children's risk of acquiring the disease by about half, according to the first results of an ongoing phase III trial. The vaccine has been developed by the British pharmaceutical giant GlaxoSmithKline's lab in Belgium. Known as RTS, the vaccine is the first of its kind to attempt to block a parasite, rather than bacteria or viruses.